Condition
Myoepithelial Tumor
Total Trials
3
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
P 1 (3)
Trial Status
Unknown2
Recruiting1
Clinical Trials (3)
Showing 3 of 3 trials
NCT06625190Phase 1Recruiting
Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
NCT03600649Phase 1Unknown
Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas
NCT05266196Phase 1Unknown
A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577)
Showing all 3 trials